U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Advisory Letters
  5. Advisory Letter - Herbalmax, Inc.
  1. Advisory Letters

Advisory Letter - Herbalmax, Inc.

Department of Health and Human Services logoDepartment of Health and Human Services

Food and Drug Administration
Silver Spring, MD 20993-0002


Sent via Email: georgeluo@herbalmax.com

August 4, 2015

Lihua Zhang and George Luo
2008 Entrada Paraiso
San Clemente, CA 92672

Re: Cancer Support Formula, Heart Formula, and Liver Formula

Dear Ms. Zhang and Mr. Luo,

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.herbalmax.com in April 2015 and has found that you offer for sale Cancer Support Formula, Heart Formula and Liver Formula in violation of the Federal Food, Drug, and Cosmetic Act. Various claims and statements made on your website and/or in other labeling cause your products to be drugs. As explained further below, the introduction of these products into interstate commerce violates 21 U.S.C. § 331(d).

Your products listed above are drugs under 21 U.S.C. § 321(g)(1)(B) because they are intended for the treatment, cure, mitigation, or prevention of cancer, hepatitis, heart attack, hypercholesterolemia (e.g., reduce cholesterol) and stroke. These products are also new drugs as defined under 21 U.S.C. § 321(p) because they are not generally recognized as safe and effective for uses recommended or suggested in their labeling. To be legally marketed, a new drug must be approved by FDA on the basis of scientific data demonstrating that the drug is safe and effective under the conditions of use in its labeling. See 21 U.S.C. §§ 355(a) and 331(d). Your drug products do not have FDA-approved applications as required by 21 U.S.C. § 355.

We advise you to review all express or implied claims you make for your products and to remove such claims that cause your products to be drugs (i.e., claims suggesting that your product is intended for treating, curing, mitigating, or preventing one or more diseases). This includes reviewing your websites, product labels, catalogs, brochures, flyers, package inserts, audio and video, e-commerce and social media accounts you operate (e.g., Amazon, eBay, Facebook and Twitter accounts), as well as any other promotional materials, and removing product claims, consumer testimonials, meta-tags, and anything else that states or implies that your products are useful in treating, curing, mitigating, or preventing diseases.

For more information on the kinds of claims that cause products to be drugs, please see 21 CFR 101.93(f)-(g) and http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucm103340.htm.

Within 30 calendar days of the date of this letter, please correct the violations described in this letter and notify FDA, via electronic mail at FDAadvisory@fda.hhs.gov or via mail to CDR Jason Humbert at 12420 Parklawn Dr., #4041, Rockville, MD 20857, that the violations have been corrected. Include the Online Advisory Letter Reference number (located in the upper right portion of this letter) in all your communications to FDA regarding this matter.

After 30 days of the date of this letter, if your website(s), labeling, or other promotional materials for the products listed above continue to recommend or suggest the use of the products to treat, cure, mitigate, or prevent diseases, your firm and these products will be listed on the FDA webpage for products illegally marketed for serious diseases.

This letter is not intended to be an all-inclusive review of your website(s) or a list of all violations of law that exist in connection with your products, your website(s) and other product labeling, or at your facilities. FDA expects you to take the necessary steps to ensure that all your products comply with the laws and regulations enforced by FDA.


Health Fraud Team
Office of Enforcement and Import Operations
Office of Regulatory Affairs
U.S. Food and Drug Administration

Back to Top